Seeking Alpha

Eileen Gu's  Instablog

Eileen Gu
Send Message
Providing industry information, market research, indepth analysis and data from China research and Intelligence. China Research and Intelligence publishes market research reports, industry analytical reports, company reports and industry databases. CRI also provides outsourcing and custom... More
My company:
China Research and Intelligence
My blog:
Marketinfoguide
  • Prostate Cancer Market To Almost Double By 2019 As New Treatments Emerge 0 comments
    Nov 26, 2013 4:31 AM

    Due to the growing prevalence of prostate cancer and the launch of new products for the condition, the prostate cancer treatment market will increase from $4.1 billion in 2012 to $8 billion by 2019, at a Compound Annual Growth Rate (OTCPK:CAGR) of 10.1%, forecasts Prostate Cancer Therapeutics Market to 2019.

    According to Prostate Cancer Therapeutics Market to 2019, the overall prevalence of prostate cancer across the eight leading markets (the US, UK, France, Germany, Italy, Spain, Japan and Canada) is expected to increase from 3.3 million in 2012 to 3.9 million by 2019.

    Prostate Cancer Therapeutics Market to 2019: "In many countries, prostate cancer is the second-most common cancer in males, excluding non-melanoma skin cancers. This contributes to a high financial burden among the elderly, with the lifetime cost of each patient amounting to around $110,520 in the US."

    The majority of the market growth will be driven by the US, where three new products are expected to be launched over the forecast period - custirsen sodium, DCVax and tasquinimod. Furthermore, Prostate Cancer Therapeutics Market to 2019 expects to see an increasing uptake of the highly priced, recently approved drugs Xofigo, Xtandi and Zytiga.

    "There are major disparities in the treatment outcomes for early-stage and late-stage cancer diagnoses, and patients diagnosed at the late-stage have a far worse prognosis. This represents a major opportunity for pharmaceutical companies to develop novel, disease-modifying drugs with improved outcomes for this patient segment," Prostate Cancer Therapeutics Market to 2019 says.

    Currently, the pipeline for prostate cancer is relatively large, with 413 products in active development. However, the failure rate for pipeline molecules is very high, with approximately 96.5% of clinical developmental programs failing to reach the market since 2006.

    Still, the market remains favorable, as this risk is offset by high potential revenues and a sufficiently high prevalent population to support the presence of several blockbuster drugs.

    Prostate Cancer Therapeutics Market to 2019- Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019

    Prostate Cancer Therapeutics Market to 2019 provides in-depth analysis of drugs available for the treatment of prostate cancer, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses.

Back To Eileen Gu's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.